Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLN) EPS (Weighted Average and Diluted) (2024 - 2025)

Silence Therapeutics' EPS (Weighted Average and Diluted) history spans 2 years, with the latest figure at -$0.09 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 212.5% year-over-year to -$0.09; the TTM value through Dec 2025 reached -$0.63, down 90.91%, while the annual FY2025 figure was -$0.63, 90.91% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$0.09 at Silence Therapeutics, up from -$0.15 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.08 in Q4 2024 and bottomed at -$0.25 in Q3 2024.